487036-63-5
Chemical Structure
MAX1
- CAS No.: 487036-63-5
- Formula:C107H201N29O21
- Molecular Weight:2229.92
InChIKey: FEWYNKZIQYPPDZ-PZXODWQNSA-N
SMILES: O=C(N1[C@@H](CCC1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@H](C(N)=O)C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@@H]2N(CCC2)C([C@H](C(C)C)NC([C@H](CCCCN)NC([C@H](C(C)C)NC([C@H](CCCCN)NC([C@H](C(C)C)NC([C@H](CCCCN)NC([C@H](C(C)C)NC([C@H](CCCCN)NC([C@@H](N)C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: MAX1 is a synthetic β-hairpin peptide that folds rapidly and self-assembles into a β-sheet-rich fibrous hydrogel network via non-covalent crosslinking. MAX1 hydrogel exhibits excellent shear-thinning and self-healing properties, enabling precise delivery via syringe and maintaining local retention after implantation. MAX1 hydrogel can uniformly encapsulate cells while preserving their viability and morphology, and protect growth factors (e.g., NGF) and chemotherapeutic drugs from degradation. MAX1 is applicable for spinal cord injury repair, medulloblastoma treatment, and three-dimensional high-throughput drug screening[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MAX1 | 95.31% | MAX1 is a synthetic β-hairpin peptide that folds rapidly and self-assembles into a β-sheet-rich fibrous hydrogel network via non-covalent crosslinking. MAX1 hydrogel exhibits excellent shear-thinning and self-healing properties, enabling precise delivery via syringe and maintaining local retention after implantation. MAX1 hydrogel can uniformly encapsulate cells while preserving their viability and morphology, and protect growth factors (e.g., NGF) and chemotherapeutic drugs from degradation. MAX1 is applicable for spinal cord injury repair, medulloblastoma treatment, and three-dimensional high-throughput drug screening. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Haines-Butterick L, et al. Controlling hydrogelation kinetics by peptide design for three-dimensional encapsulation and injectable delivery of cells. Proceedings of the National Academy of Sciences of the United States of America. 2007 May 08;104(19):7791-6. [Content Brief]
- [2]. Lindsey S, et al. Beta Hairpin Peptide Hydrogels as an Injectable Solid Vehicle for Neurotrophic Growth Factor Delivery. Biomacromolecules. 2015 Sep 14;16(9):2672-83. [Content Brief]
- [3]. Hule RA, et al. Correlations between structure, material properties and bioproperties in self-assembled beta-hairpin peptide hydrogels. Faraday discussions. 2008;139:251-64; discussion 309-25, 419-20. [Content Brief]
- [4]. Branco MC, et al. Fast dynamics of semiflexible chain networks of self-assembled peptides. Biomacromolecules. 2009 Jun 08;10(6):1374-80. [Content Brief]
- [5]. Leonard SR, et al. Solid-state NMR evidence for β-hairpin structure within MAX8 designer peptide nanofibers. Biophysical journal. 2013 Jul 02;105(1):222-30. [Content Brief]
- [6]. Sun JE, et al. Sustained release of active chemotherapeutics from injectable-solid β-hairpin peptide hydrogel. Biomaterials science. 2016 May 26;4(5):839-48. [Content Brief]
Keywords
